Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Figure 1
Kaplan-Meier plot of time to progression (TTP) in 36 patients treated with biweekly gemcitabine and docetaxel. Median TTP was 2.3 months (95% CI: 1.5–3.8 months). The 3-month TTP rate was 45% (95% CI: 27–63%). The 6-month TTP rate was 17% (95% CI: 1–32%).
